Organic compounds -- part of the class 532-570 series – Organic compounds – Carbohydrates or derivatives
Reexamination Certificate
2006-02-07
2006-02-07
Lacourciere, Karen A. (Department: 1635)
Organic compounds -- part of the class 532-570 series
Organic compounds
Carbohydrates or derivatives
C536S024300, C435S006120, C435S091100, C435S091300
Reexamination Certificate
active
06995258
ABSTRACT:
The HIV regulatory proteins Tat and Rev accumulate in nucleoli of human cells. No functional role has been attributed to this localization. Recently it was demonstrated that expression of Rev induces nucleolar re-localization of some nuclear factors involved in Rev export. Thus, it is likely that the nucleolus plays a critical role in Rev-mediated export of singly spliced and unspliced HIV-1 RNAs. As a test for trafficking of HIV-1 RNAs into the nucleolus, a hammerhead ribozyme which specifically cleaves HIV-1 RNA was joined to the U16 snoRNA resulting in accumulation of the ribozyme within nucleoli of human cells. Stably transduced human T-cells expressing this nucleolar localized ribozyme dramatically suppressed HIV-1 replication, confirming a possible trafficking of the HIV RNA through the nucleoli of human cells. In addition, a TAR element which binds Tat was joined to the U16 snoRNA, also resulting in localization in the nucleoli and inhibiting HIV replication.
REFERENCES:
Browning et al., “Potent Inhibition of Human Immunodeficiency Virus Type 1 (HIV-1) Gene Expression and Virus Production by an HIV-2 Tat Activation-Response RNA Decoy,” J. Virol 73(6):5191-5195, 1999.
Buonomo et al., “The Rev protein is able to transport to the cytoplasm small nucleolar RNAs containing a Rev binding element,” RNA 5:993-1002, 1999.
Caffarelli et al., “In Vivo Identification of Nuclear Factors Interfacing with the Conserved Elements of Box C/D Small Nucleolar RNAs,” Mol. Cell Biol. 18(2):1023-1028, 1998.
Cagnon et al.. “Protection of a T-Cell Line from Human Immunodeficiency Virus Replication by the Stable Expression of a Short Antisense RNA Sequence Carried by a Shuffle RNA Molecule,” J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 9:349-358, 1995.
Cagnon et al., “Retroviral Delivery and Anti-HIV Testing of Hammerhead Ribozymes,” Methods in Molecular Bilolgy 74:451-457, 1997, Ribozyme Protocols, P. C. Turner (ed.), Humana Press, Inc., Totowa, NJ.
Churcher et al., “The RNA element encoded by the trans-activation-responsive region of human immunodeficiency virus type 1 is functional when displaced downstream of the start of transcription,” Proc. Natl. Acad. Sci. USA 92:2408-2412, Mar. 1995.
Cullen et al., “Subcellular Localization of the Human Immunodefeciency Virus trans-Acting art Gene Product,” J. Virol. 62:2498-2501, Jul. 1988.
Dayton et al., “The Trans-Activator Gene of the Human T Cell Lymphotropic Virus Type III Is Required for Replication,” Cell 44:941-947, Mar. 28, 1986.
Dingwall et al., “Human immunodeficiency virus 1 tat protein binds trans-activation-responsive region (TAR) RNA in vitro,” Proc. Natl. Acad. Sci. USA 86:6925-6929, Sep. 1989.
Feng et al., “HIV-1 tat trans-activation requires the loop sequence within tar,” Nature (London) 334:165-167, Jul. 14, 1988.
Fisher et al., “The trans-activator gene of HTLV-III is essential for virus replication,” Nature 320:367-371, Mar. 27, 1986.
Fragapane et al., “A novel small nucleolar RNA (U16) is encoded inside a ribosomal protein intron and originates by processing of the pre-mRNA,” EMBO J. 12(7):2921-2928, 1993.
Gait et al., “RNA recognition by the human immuno-deficiency virus Tat and Rev proteins,” Trends in Biochem. Sci. 18:255-259, 1993.
Good et al., “Expression of small, therapeutic RNAs in human cell nuclei,” Gene Ther. 4:45-54, 1997.
Gorse et al., “Antibody to Native Human Immunodeficiency Virus Type 1 Envelope Glycoproteins Induced by HIB and MN Recombinant gp 120 Vaccines,” Clinical and Diagnostic Laboratory Immunology 3(4):378-386, Jul. 1996.
Haseloff et al., “Simple RNA enzymes with new and highly specific endoribonuclease activities,” Nature 334:585-591, Aug. 18, 1988.
Hertel et al., “Numbering system for the hammerhead,” Nucleic Acids Res. 20(12):3252, 1992.
Kalland et al., “Rex-Dependent Nucleolar Accumulation of HTLV-1 mRNAs,” The New Biologist 3(4):389-397, 1991.
Konopka et al., “Receptor Ligand-Facilitated Cationic Liposome Delivery of Anti-HIV-1 Rev-Binding Aptamer and Ribozyme DNAs,” J. Drug Targeting 5(4):247-259, 1998.
Lafontaine et al., “Birth of the snoRNPs: the evolution of the modification-guide snoRNAs,” Trends in Biochem. Sci. 23:383-388, Oct. 1998.
Lange et al., “Conserved Boxes C and D are essential nucleolar localization elements of U14 and U8 snoRNAs,” EMBO J. 17(11):3176-3187, 1998.
Lee et al., “mRNA localization signals can enhance the intracelluar effectiveness of hammerhead ribozymes,” RNA 5:1200-1209, 1999.
Michienzi et al., “Ribozyme-mediated inhibition of HIV 1 suggests nucleolar trafficking of HIV-1 RNA,” PNAS 97(16):8955-8960, Aug. 1, 2000.
Michienzi et al., “A chimeric nucleolar Rev decoy inhibits the HIV replication,” Nucleic Acids Symposium Series No. 41:211-214, 1999.
Michienzi et al., “Inhibition of Human Immunodeficiency Virus Type 1 Replication by Nuclear Chimeric Anti-HIV Ribozymes in a Human T Lymphoblastoid Cell Line,” Hum. Gene Ther. 9:621-628, Mar. 20, 1998.
Muesing et al., “Regulation of mRNA Accumulation by a Human Immunodeficiency Virus Trans-Activator Protein,” Cell 48:691-701, Feb. 27, 1987.
Müller et al., “Stimulation of HIV-1 neutralizing antibodies in simian HIV-IIIB-infected macaques,” Proc. Natl. Acad. Sci. USA 9:276-281, Jan. 1998.
Ojwang et al., “Inhibition of Human Immunodeficiency virus type 1 expression by a hairpin ribozyme,” Proc. Natl. Acad. Sci. USA 89:10802-10806, Nov. 1992.
Pederson, “Survey and Summary, The plurifunctional nucleolus,” Nucleic Acids Res. 26(17):3871-3876, 1998.
Prislei et al., “Use of adenoviral VAI small RNA as a carrier for cytoplasmic delivery of ribozymes,” RNA 3:677-687, 1997.
Prislei et al., “Two different snoRNAs are encoded in introns of amphibian and human L1 ribosdomal protein genes,” Nucleic Acids Res. 21(25):5824-5830, 1993.
Ratner et al., “Complete nucleotide sequence of the AIDS virus, HTLV-III,” Nature 313:277-284, Jan. 24, 1985.
Rosen et al., “The Location of Cis-Acting Regulatory Sequences in the Human T Cell Lymphotropic Virus Type III (HTLV-III/LAV) Long Terminal Repeat,” Cell 41:813-823, Jul. 1985.
Rossi, “Ribozymes in the Nucleolus,” Science 285:1685, Sep. 10, 1999.
Rossi, “Ribozymes, genomics and therapeutics,” Chemistry & Biology 6:R33-37, 1999.
Ruffner et al., “Sequence Requirements of the Hammerhead RNA Self-Cleavage Reaction,” Biochemistry 29:10695-10702, 1990.
Samarsky et al., “The snoRNA box D/D motif directs nucleolar targeting and also couples snoRNA synthesis and localization,” EMBO J. 17(13):3747-3757, 1998.
Samarsky et al., “A small nucleolar RNA:ribozyme hybrid cleaves a nucleolar RNA target in vivo with near-perfect efficiency,” Proc. Natl. Acad. Sci. USA 96:6609-6614, Jun. 1999.
Sheline et al., “Two distinct nuclear transcription factors recognize loop and bulge residues of the HIV-1 TAR RNA hairpin,” Genes & Development 5:2508-2520, 1991.
Siomi et al., “Sequence Requirements for Nucleolar Localization of Human T Cell Leukemia Virus Type 1 pX protein, Which Regulates Viral RNA Processing,” Cell 55:197-209, Oct. 21, 1988.
Stauber et al., “Intracellular Trafficking and Interactions of the HIV-1 Tat Protein,” Virology 252:126-136, 1998.
Sullenger et al., “Analysis of trans-Acting Response Decoy RNA-Mediated Inhibition of Human Immunodeficiency Virus Type 1 Transactivation,” J. Virol. 65(12)6811-6816, Dec. 1991.
Sullenger et al., “Tethering Ribozymes to Retroviral Packaging Signal for Destruction of Viral DNA,” Science 262:1566-1569, Dec. 3, 1993.
Uhlenbeck, “A small catalytic oligoribonucleotide,&#x
Michienzi Alessandro
Rossi John J.
City of Hope
Lacourciere Karen A.
Rothwell Figg Ernst & Manbeck
LandOfFree
Nucleolar targeting of therapeutics against HIV does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Nucleolar targeting of therapeutics against HIV, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Nucleolar targeting of therapeutics against HIV will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3689446